Kuzniecky R, Pan J, Burns A, Devinsky O, Hetherington H
NYU Epilepsy Center, Department of Neurology, New York University School of Medicine, New York, NY 10016, USA.
Epilepsy Behav. 2008 Feb;12(2):242-4. doi: 10.1016/j.yebeh.2007.09.020.
The mechanism of action of levetiracetam (LEV), an antiepileptic drug, is related to a novel binding site, SV2, but LEV acts on GABA-A receptors. The objective of the study described here was to determine if LEV modulates brain GABA in vivo.
Concentrations of cerebral GABA and serum LEV were obtained in seven healthy individuals using 1H magnetic resonance spectroscopy at baseline and 3 and 6 hours following oral administration of 1 g of LEV.
Brain cerebral GABA acutely concentrations did not change from baseline.
The results indicate that LEV does not increase human cerebral GABA concentrations acutely in healthy individuals.
抗癫痫药物左乙拉西坦(LEV)的作用机制与一个新的结合位点SV2有关,但LEV作用于GABA - A受体。本文所述研究的目的是确定LEV在体内是否调节脑内GABA。
对7名健康个体在基线时以及口服1 g LEV后3小时和6小时,使用氢磁共振波谱法测定脑内GABA浓度和血清LEV浓度。
脑内GABA的急性浓度与基线相比没有变化。
结果表明,在健康个体中,LEV不会急性增加人脑内GABA浓度。